Identification

Name
Potassium Iodide
Accession Number
DB06715
Type
Small Molecule
Groups
Approved
Description

Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperglycemia (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyroidectomy.

Structure
Thumb
Synonyms
  • Kaliumiodid
  • KI
  • Potassium iodide
External IDs
NSC-77362
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ThyroSafeTablet65 mgOralRecip Ab2003-11-042008-07-07Canada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Iodine Ctr Srt 300mgTablet, extended release300 mcgOralBioenergy Inc.1979-12-311998-06-03Canada
IosatTablet65 mg/1OralAnbex Inc.2013-05-01Not applicableUs
IosatTablet130 mg/1OralAnbex Inc.1982-10-14Not applicableUs
Potassium IodideSolution65 mg/mLOralMission Pharmacal2016-05-15Not applicableUs
Thyroblock Tab 130mgTablet130 mgOralCarter Horner Corp.1981-12-312003-03-14Canada
ThyroSafeTablet65 mg/1OralRecipharm Ab (Publ)2002-09-30Not applicableUs
ThyroShieldSolution65 mg/mLOralArco Pharmaceuticals LLC2014-09-01Not applicableUs
ThyroShieldSolution65 mg/mLOralFleming & Company, Pharmaceuticals2005-04-01Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SskiSolution1 g/mLOralUpsher Smith Laboratories, Llc1973-04-30Not applicableUs
SskiSolution1 g/mLOralAvondale Pharmaceuticals, Llc2017-11-13Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Central-vite 18 EssentialPotassium Iodide (0.15 mg) + Beta carotene (3000 unit) + Biotin (45 mcg) + Calcium (175 mg) + Calcium Phosphate (125 mg) + Cholecalciferol (400 unit) + Cupric oxide (2 mg) + Cyanocobalamin (9 mcg) + Folic Acid (0.4 mg) + Ferrous fumarate (10 mg) + Magnesium (100 mg) + Nicotinamide (40 mg) + Calcium pantothenate (10 mg) + Pyridoxine hydrochloride (3 mg) + Riboflavin (3.2 mg) + Thiamine mononitrate (2.25 mg) + Vitamin A (2000 unit) + Vitamin C (90 mg) + Vitamin E (25 unit)TabletOralVita Health Products Inc1998-04-242002-07-31Canada
Century CompletePotassium Iodide (.15 mg) + Beta carotene (3000 unit) + Biotin (45 mcg) + Calcium (175 mg) + Calcium Phosphate (125 mg) + Cupric oxide (2 mg) + Cyanocobalamin (9 mcg) + Folic Acid (.4 mg) + Ferrous fumarate (10 mg) + Magnesium (100 mg) + Nicotinamide (40 mg) + Calcium pantothenate (10 mg) + Pyridoxine hydrochloride (3 mg) + Riboflavin (3.2 mg) + Thiamine mononitrate (2.25 mg) + Vitamin A (2000 unit) + Vitamin C (90 mg) + Vitamin D (400 unit) + Vitamin E (25 unit)TabletOralVita Health Products Inc1998-03-172002-07-31Canada
Children's Chewable Multivitamin and MultimineralPotassium Iodide (0.15 mg) + Beta carotene (250 unit) + Biotin (20 mcg) + Calcium (162 mg) + Calcium Phosphate (125 mg) + Cupric oxide (2 mg) + Cyanocobalamin (5 mcg) + Folic Acid (0.3 mg) + Ferrous fumarate (4 mg) + Nicotinamide (15 mg) + Calcium pantothenate (5 mg) + Pyridoxine hydrochloride (1.7 mg) + Riboflavin (1.4 mg) + Thiamine mononitrate (1.2 mg) + Vitamin A (2750 unit) + Vitamin C (60 mg) + Vitamin D (400 unit) + Vitamin E (15 unit)TabletOralJamieson Laboratories Ltd2006-09-202009-07-29Canada
CitraNatal 90 DHAPotassium Iodide (150 ug/1) + Calcium Citrate (159 mg/1) + Cupric oxide (2 mg/1) + Docusate sodium (50 mg/1) + Folic Acid (1 mg/1) + Iron (85 mg/1) + Ferrous gluconate (5 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (3.4 mg/1) + Thiamine (3 mg/1) + Thiamine mononitrate (4.54 mg/1) + Vitamin C (120 mg/1) + Vitamin D (400 [iU]/1) + Vitamin E acetate (30 [iU]/1) + Zinc oxide (25 mg/1)TabletOralMission Pharmacal2014-04-11Not applicableUs
CitraNatal DHAPotassium Iodide (150 mg/1) + Calcium Citrate (125 mg/1) + Cupric oxide (2 mg/1) + Docusate sodium (50 mg/1) + Folic Acid (1 mg/1) + Iron (27 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (3.4 mg/1) + Thiamine (3 mg/1) + Vitamin C (120 mg/1) + Vitamin D (400 [iU]/1) + Vitamin E acetate (30 [iU]/1) + Zinc oxide (25 mg/1)TabletOralMission Pharmacal2007-11-20Not applicableUs
CitraNatal RxPotassium Iodide (150 mg/1) + Calcium Citrate (124 mg/1) + Cupric oxide (2 mg/1) + Folic Acid (1 mg/1) + Iron (27 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (3.4 mg/1) + Thiamine (3 mg/1) + Vitamin C (120 mg/1) + Vitamin D (400 [iU]/1) + Vitamin E acetate (30 [iU]/1) + Zinc oxide (25 mg/1)TabletOralMission Pharmacal2014-08-11Not applicableUs
CitraNatal RxPotassium Iodide (150 mg/1) + Calcium Citrate (125 mg/1) + Cupric oxide (2 mg/1) + Docusate sodium (50 mg/1) + Folic Acid (1 mg/1) + Iron (27 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (3.4 mg/1) + Thiamine (3 mg/1) + Vitamin C (120 mg/1) + Vitamin D (400 [iU]/1) + Vitamin E acetate (30 [iU]/1) + Zinc oxide (25 mg/1)TabletOralMission Pharmacal2007-11-26Not applicableUs
Complete Multivitamins and Minerals Tablets Timed ReleasePotassium Iodide (0.1 mg) + Beta carotene (5000 unit) + Biotin (50 mcg) + Calcium (125 mg) + Choline bitartrate (50 mg) + Chromium (25 mcg) + Copper (1 mg) + Folic Acid (0.4 mg) + Inositol nicotinate (50 mg) + Iron (15 mg) + Magnesium (100 mg) + Manganese (1 mg) + Nicotinamide (50 mg) + Calcium pantothenate (50 mg) + Potassium (25 mg) + Pyridoxine hydrochloride (50 mg) + Riboflavin (50 mg) + Selenium (25 mcg) + Thiamine mononitrate (50 mg) + Vitamin A (5000 unit) + Vitamin C (150 mg) + Vitamin D (400 unit) + Vitamin E (75 unit) + Zinc (10 mg)Tablet, extended releaseOralPharmetics (2011) Inc.1999-07-262009-07-30Canada
DiodinePotassium Iodide (750 mg) + Iodine (750 mg) + Isopropyl Alcohol (25.11 ml)LiquidTopicalProduits Marc O (1987) Inc., Division Of Technilab Inc.1980-06-051999-09-17Canada
Earthpals Children's Chewables Multi-vitamin & Mineral TabletsPotassium Iodide (0.075 mg) + Beta carotene (1500 unit) + Biotin (10 mcg) + Calcium (125 mg) + Copper (1 mg) + Cyanocobalamin (5 mcg) + Folic Acid (0.2 mg) + Magnesium (50 mg) + Nicotinamide (10 mg) + Calcium pantothenate (5 mg) + Pyridoxine hydrochloride (1 mg) + Riboflavin (0.85 mg) + Thiamine Hydrochloride (0.75 mg) + Vitamin A (1000 unit) + Vitamin C (30 mg) + Vitamin D (200 unit) + Vitamin E (12.5 unit)TabletOralHeritageNot applicableNot applicableCanada
Categories
UNII
1C4QK22F9J
CAS number
7681-11-0
Weight
Average: 166.0028
Monoisotopic: 165.868175281
Chemical Formula
IK
InChI Key
NLKNQRATVPKPDG-UHFFFAOYSA-M
InChI
InChI=1S/HI.K/h1H;/q;+1/p-1
IUPAC Name
potassium iodide
SMILES
[K+].[I-]

Pharmacology

Indication

Potassium Iodide is oral antithyroid agent. Potassium Iodide is used as an adjunct to other antithyroid agents in the treatment of hyperthyroidism and thyrotoxicosis and preoperatively to induce thyroid involution.

Structured Indications
Pharmacodynamics

It works in the thyroid gland. By inhibiting thyroid hormone synthesis and release, thyroid gland vascularity is reduced, thyroid gland tissue becomes firmer, thyroid cell size is reduced, follicular colloid reaccumulates, and bound iodine levels increase. As a protectant following radiation exposure, KI blocks the uptake of radioactive iodine isotopes by the thyroid gland thereby minimizing the risk of radiation-induced thyroid neoplasms.

Mechanism of action
TargetActionsOrganism
UTyrosine
binder
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcenocoumarolPotassium Iodide may decrease the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Potassium Iodide.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be increased when it is combined with Potassium Iodide.Experimental
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Potassium Iodide.Experimental, Investigational
ClorindionePotassium Iodide may decrease the anticoagulant activities of Clorindione.Experimental
CymarinThe serum concentration of Cymarin can be increased when it is combined with Potassium Iodide.Experimental
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Potassium Iodide.Approved
DicoumarolPotassium Iodide may decrease the anticoagulant activities of Dicoumarol.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Potassium Iodide.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Potassium Iodide.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Potassium Iodide.Approved
DiphenadionePotassium Iodide may decrease the anticoagulant activities of Diphenadione.Experimental
Ethyl biscoumacetatePotassium Iodide may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
FluindionePotassium Iodide may decrease the anticoagulant activities of Fluindione.Investigational
GitoformateThe serum concentration of Gitoformate can be increased when it is combined with Potassium Iodide.Experimental
Iodide I-131The therapeutic efficacy of Iodide I-131 can be decreased when used in combination with Potassium Iodide.Approved
Lanatoside CThe serum concentration of Lanatoside C can be increased when it is combined with Potassium Iodide.Experimental
LithiumPotassium Iodide may increase the hypothyroid activities of Lithium.Approved
MetildigoxinThe serum concentration of Metildigoxin can be increased when it is combined with Potassium Iodide.Experimental
OleandrinThe serum concentration of Oleandrin can be increased when it is combined with Potassium Iodide.Experimental, Investigational
OuabainThe serum concentration of Ouabain can be increased when it is combined with Potassium Iodide.Approved
PeruvosideThe serum concentration of Peruvoside can be increased when it is combined with Potassium Iodide.Experimental
PhenindionePotassium Iodide may decrease the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonPotassium Iodide may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
ProscillaridinThe serum concentration of Proscillaridin can be increased when it is combined with Potassium Iodide.Experimental
TioclomarolPotassium Iodide may decrease the anticoagulant activities of Tioclomarol.Experimental
WarfarinPotassium Iodide may decrease the anticoagulant activities of Warfarin.Approved
Food Interactions
Not Available

References

Synthesis Reference

Stanley D. Lazarus, "Production of thermally stabilized polyester with alkylene carbonates and sodium or potassium iodide." U.S. Patent US4327207, issued October, 1973.

US4327207
General References
Not Available
External Links
KEGG Drug
D01016
KEGG Compound
C08219
PubChem Compound
4875
PubChem Substance
99443267
ChemSpider
4709
ChEBI
8346
ChEMBL
CHEMBL1141
PharmGKB
PA451060
Wikipedia
SSKI
ATC Codes
R05CA02 — Potassium iodideV03AB21 — Potassium iodideS01XA04 — Potassium iodide
AHFS Codes
  • 68:36.08 — Antithyroid Agents
  • 48:16.00 — Expectorants
  • 88:29.00* — Minerals

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentMalignant Lymphomas1
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
3CompletedPreventionCariostatic Agents / Dental Decay1
3CompletedTreatmentDental Plaque1
3RecruitingPreventionHeart Failure, Unspecified1
3TerminatedTreatmentPregnancy1
4CompletedDiagnosticCoronary Artery Disease / Coronary Stenosis1
4CompletedTreatmentGraves Diseases / Hyperthyroidism1
4CompletedTreatmentHyperemesis Gravidarum / Morning Sickness / Nausea / Pregnancy / Vomiting1
4CompletedTreatmentPregnancy1
4Unknown StatusTreatmentAmputation Wound / Wound Infections1
Not AvailableRecruitingTreatmentMetastatic Pheochromocytoma / Relapsed Neuroblastoma1
Not AvailableRecruitingTreatmentRoot Canal Disinfection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, extended releaseOral
LiquidTopical
LiquidOral
Tablet, extended releaseOral300 mcg
TinctureTopical
TabletOral130 mg/1
Tablet, effervescentOral
SolutionTopical
LiquidIntravenous
SyrupOral
CapsuleOral
Capsule, liquid filledOral
TabletOral
Tablet, coatedOral
PowderOral
Kit
PowderTopical
SolutionOral1 g/mL
TabletOral130 mg
TabletOral65 mg
TabletOral65 mg/1
SolutionOral65 mg/mL
Tablet, film coatedOral
Capsule, gelatin coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP0.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7647
Blood Brain Barrier+0.9702
Caco-2 permeable+0.6625
P-glycoprotein substrateNon-substrate0.8989
P-glycoprotein inhibitor INon-inhibitor0.984
P-glycoprotein inhibitor IINon-inhibitor0.9854
Renal organic cation transporterNon-inhibitor0.9282
CYP450 2C9 substrateNon-substrate0.8261
CYP450 2D6 substrateNon-substrate0.7789
CYP450 3A4 substrateNon-substrate0.7857
CYP450 1A2 substrateNon-inhibitor0.7164
CYP450 2C9 inhibitorNon-inhibitor0.8527
CYP450 2D6 inhibitorNon-inhibitor0.9142
CYP450 2C19 inhibitorNon-inhibitor0.8842
CYP450 3A4 inhibitorNon-inhibitor0.9317
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9022
Ames testNon AMES toxic0.6838
CarcinogenicityCarcinogens 0.659
BiodegradationNot ready biodegradable0.5913
Rat acute toxicity2.9202 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9535
hERG inhibition (predictor II)Non-inhibitor0.9657
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as alkali metal iodides. These are inorganic compounds in which the largest halogen atom is Iodine, and the heaviest metal atom is an alkali metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Alkali metal salts
Sub Class
Alkali metal iodides
Direct Parent
Alkali metal iodides
Alternative Parents
Inorganic salts
Substituents
Alkali metal iodide / Inorganic salt
Molecular Framework
Not Available
External Descriptors
potassium salt (CHEBI:8346)

Targets

Kind
Small molecule
Organism
Human
Pharmacological action
Unknown
Actions
Binder
References
  1. Pisarev MA, Aiello LO: Studies on the mechanism of action of potassium iodide on thyroid protein biosynthesis. Acta Endocrinol (Copenh). 1976 Jun;82(2):298-305. [PubMed:946922]
  2. Foldes J, Gesztesi E, Juhasz J: Mechanism of action of di-iodotyrosine and of iodine. Acta Med Acad Sci Hung. 1974;31(1-2):131-7. [PubMed:4464746]

Drug created on May 16, 2010 17:39 / Updated on January 15, 2018 08:56